Sign in

    Justin Zelin • BTIG

    Justin Zelin's questions to Legend Biotech Corp (LEGN) leadership

    Justin Zelin's questions to Legend Biotech Corp (LEGN) leadership • Q2 2025

    Question

    Justin Zelin asked about the company's strategy for reinvesting capital once it reaches profitability and whether recent U.S. tariff changes are expected to have a material impact on manufacturing costs or the supply chain.

    Answer

    Interim CFO Jessie Yeung stated that while the company is disciplined with spending, it is committed to reinvesting in next-generation cell therapies. Regarding tariffs, she explained that because U.S. products are predominantly made and sourced in the U.S., the company does not anticipate any material exposure based on current evaluations.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Legend Biotech Corp (LEGN) leadership • Q4 2024

    Question

    On behalf of Justin Zelin, an analyst asked about the ultimate potential percentage of patients that could be treated in the outpatient setting and how to model capital expenditures going forward.

    Answer

    Executive Alan Bash stated that they see continued growth in outpatient use and have not modeled a specific cap or ceiling, as centers that start with inpatient use tend to quickly adopt outpatient protocols. Executive Jessie Yeung commented on CapEx, stating that while investment continues worldwide, the bulk of it will be completed in 2025.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Legend Biotech Corp (LEGN) leadership • Q3 2024

    Question

    On behalf of Justin Zelin, Jed asked if clinician hesitancy due to neurotoxicity concerns remains a factor in the second-line setting. He also inquired about the launch trajectory for CARVYKTI in China.

    Answer

    SVP Steven Gavel acknowledged that toxicity is a key consideration in earlier lines, which is why educational efforts have been increased, but noted the strong OS data helps ease concerns. CEO Ying Huang explained that due to supply priorities, the U.S. and European markets are being prioritized over China for now. He also confirmed that U.S./EU production uses no raw materials from China, mitigating any potential tariff impact.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Verastem Inc (VSTM) leadership

    Justin Zelin's questions to Verastem Inc (VSTM) leadership • Q2 2025

    Question

    Justin Zelin asked if the $2.1 million in Q2 revenue reflects true patient demand with minimal channel stocking, given the use of specialty pharmacies. He also inquired about expectations for future inventory stocking and any early insights on gross-to-net dynamics and payer mix.

    Answer

    President and CEO Dan Paterson confirmed that due to the use of only two specialty pharmacies and tight inventory controls, the revenue reflects patient demand with minimal stocking. CFO Dan Calkins added that while it's too early for specific guidance on gross-to-net, an expectation of 15% to 20%, typical for other small molecule oncology drugs, is not unreasonable.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Immunocore Holdings PLC (IMCR) leadership

    Justin Zelin's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2025

    Question

    Justin Zelin from BTIG inquired about specific new markets for ChemTrak launches and the company's strategy for them, as well as the most effective tactics for driving growth in the U.S. community setting.

    Answer

    Ralph Torbay, EVP of Commercial, highlighted ongoing launches in the UK, Poland, and the Netherlands, and a new partnership with Air Chem for Turkey and the MENA region. For U.S. community growth, he mentioned leveraging data-driven triggers and AI to smartly predict where patients are and deploy resources efficiently, rather than expanding operations.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Immunocore Holdings PLC (IMCR) leadership • Q4 2024

    Question

    Justin Zelin of BTIG inquired about the expected safety and tolerability profile for Immunocore's pipeline candidates outside of oncology, specifically in infectious and autoimmune diseases. He also asked about the minimum commercially successful TPP regarding adverse events like cytokine release syndrome (CRS) in these settings.

    Answer

    David Berman, Head of R&D, explained that for infectious diseases, only mild CRS is expected, whereas for autoimmune diseases, no CRS is anticipated because the mechanism turns the immune system off rather than on. He highlighted that the tissue-specific platform is designed to avoid systemic immunosuppression. CEO Bahija Jallal added that the ongoing dose escalation in the HIV trial beyond 300 micrograms suggests a very good safety profile.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Justin Zelin from BTIG inquired about the timeline for the autoimmune disease programs to enter the clinic, noting that CMC manufacturing has commenced.

    Answer

    CEO Bahija Jallal responded that with CMC manufacturing going well, the company is hopeful that the autoimmune programs will enter the clinic by next year.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Justin Zelin from BTIG inquired about the timeline for the company's autoimmune disease programs to enter the clinic, noting that CMC manufacturing for candidates is underway.

    Answer

    CEO Bahija Jallal responded that CMC manufacturing is progressing well and that the company is 'hoping by next year' for the autoimmune programs to enter the clinic.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Syndax Pharmaceuticals Inc (SNDX) leadership

    Justin Zelin's questions to Syndax Pharmaceuticals Inc (SNDX) leadership • Q2 2025

    Question

    Justin Zelin asked about the commercial preparations for the anticipated NPM1 label expansion for Revuforge and whether the uptake is expected to be immediate and meaningful or more gradual.

    Answer

    CCO Steve Closter explained that the commercial team is well-prepared as they are already targeting the same physicians who are now experienced with Revuforge. He anticipates a significant 'bump' in uptake upon approval, not a gradual one, given the strong data and low off-label use. CEO Michael Metzger emphasized that the expansion triples the addressable patient population, making it a major growth driver.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Syndax Pharmaceuticals Inc (SNDX) leadership • Q4 2024

    Question

    Justin Zelin of BTIG questioned the company's confidence in receiving a broad NCCN recommendation for NPM1, asked about payer discussions for this indication ahead of FDA approval, and inquired about the strategic importance of being first-to-market.

    Answer

    CEO Michael Metzger expressed high confidence in NCCN inclusion due to the practice-changing data. CCO Steven Closter explained that payer discussions for NPM1 will begin after the sNDA is filed, but noted payers are currently reimbursing based on unmet need. He emphasized that the first-mover advantage is critical for building "competitive immunity" through superior customer experience.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Syndax Pharmaceuticals Inc (SNDX) leadership • Q3 2024

    Question

    Justin Zelin from BTIG, LLC inquired whether a companion diagnostic would be required for the approval of Revumenib for the KMT2A indication.

    Answer

    CEO Michael Metzger responded that while there is precedent for a companion diagnostic to be required post-approval, the company is confident in its path to approval given the availability of existing and robust testing methods for KMT2A. He indicated more details would be provided after the regulatory decision.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Viking Therapeutics Inc (VKTX) leadership

    Justin Zelin's questions to Viking Therapeutics Inc (VKTX) leadership • Q2 2025

    Question

    Justin Zelin of BTIG inquired about the plan for using auto-injectors in the Phase III VANQUISH studies and whether a bridging study would be required for their implementation.

    Answer

    President & CEO Brian Lian confirmed that the company plans to transition patients to auto-injectors early next year. He also stated that a bioequivalence study will be conducted in the interim to assess the auto-injector relative to the current vial and syringe format.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Viking Therapeutics Inc (VKTX) leadership • Q4 2024

    Question

    Justin Zelin asked for commentary on upcoming data from oral small molecule obesity competitors and the relative scalability of peptide API compared to small molecules.

    Answer

    CEO Brian Lian declined to speculate on competitor data. He addressed what he called a 'misperception' about manufacturing, stating that while peptide chemistry is simple, scalability is the main challenge. He expressed confidence in Viking's ability to produce at a scale that supports a multi-billion dollar franchise.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Viking Therapeutics Inc (VKTX) leadership • Q3 2024

    Question

    Justin Zelin inquired whether the Phase III study for subcutaneous VK2735 would use an auto-injector and asked for clarification on the clinical development path for VK0214 in X-ALD, specifically if the next step would be a registrational trial.

    Answer

    Brian Lian, an executive, confirmed that an auto-injector will be used in the Phase III study, either from the start or by transitioning patients during the trial. For the X-ALD program, he affirmed the expectation that the next step would be a registrational study focused on a functional or quality-of-life endpoint, moving beyond biomarkers.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Zymeworks Inc (ZYME) leadership

    Justin Zelin's questions to Zymeworks Inc (ZYME) leadership • Q4 2024

    Question

    Justin Zelin asked about the desired target product profile for ZW251 to ensure differentiation and inquired about the linker stability and expected toxicity profile of ZW191 compared to other technologies.

    Answer

    CSO Dr. Paul Moore explained that for ZW251, the goal is to meet or exceed current benchmarks in HCC, leveraging the broad expression of the GPC3 target. For ZW191, he described the linker as having traditional stability, not a highly stable one, which is part of a design philosophy focused on creating a tolerable profile to enable higher dosing and future combination strategies, a concept supported by preclinical data.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Kura Oncology Inc (KURA) leadership

    Justin Zelin's questions to Kura Oncology Inc (KURA) leadership • Q4 2024

    Question

    Justin Zelin of BTIG asked about the wholly-owned farnesyl transferase inhibitor (FTI) programs, specifically if Kura has preclinical data with pan-KRAS inhibitors. He also inquired about the company's business development strategy for the remainder of the year.

    Answer

    CEO Troy Wilson confirmed they have non-clinical data showing synergistic activity with both mutant-selective and pan-RAS inhibitors. Regarding business development, he stated the bar for in-licensing is very high, and the focus is on clinical collaborations rather than out-licensing, with the notable exception of the diabetes program, which may be partnered.

    Ask Fintool Equity Research AI

    Justin Zelin's questions to Kura Oncology Inc (KURA) leadership • Q3 2024

    Question

    Justin Zelin from BTIG inquired if Kura plans to analyze for resistance mutations in its combination and earlier-line studies and what their expectations are for those findings.

    Answer

    EVP of Clinical Development, Dr. Mollie Leoni, stated they do not expect baseline resistance in frontline settings. She explained that the risk of developing resistance decreases enormously in combination therapy because it 'hits it harder and faster,' preventing resistant colonies from growing. Therefore, she anticipates fewer issues with mutations in combination settings.

    Ask Fintool Equity Research AI